Liraglutide can prevent PAD progression in patients with type 2 diabetes: STARDUST trial
Italy: Compared with conventional treatment, liraglutide use over six months was associated with increased peripheral in patients with type 2 diabetes and peripheral artery disease (PAD), suggesting that it may prevent PAD’s clinical progression, a recent study has shown. “The open-label randomized clinical trial (STARDUST) of 55 patients with T2D and PAD showed that liraglutide […]